RxDoctor Payments Data

Roger Buck, MD

Family Medicine · Gadsden, ALNPI 1871593566

Payments from drug & device makers

$2,256in general payments, 2019–2025

Across 140 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$597
  • AbbVie$288
  • Pfizer$209
  • AstraZeneca$146
  • Amgen$123
  • Boehringer Ingelheim$107
  • plus $786 from 16 others

What the payments were for

  • Food & beverage$2,24499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,256 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$66,686
Medicare patients
297
Services billed
1,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide60$97,931
OzempicSemaglutide61$96,764
MounjaroTirzepatide63$78,287
FarxigaDapagliflozin Propanediol40$54,919
JardianceEmpagliflozin41$54,677
EliquisApixaban54$54,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$49,316
JanuviaSitagliptin Phosphate18$27,958
RybelsusSemaglutide11$17,687
LinzessLinaclotide23$13,259
Butorphanol Tartrate12$12,285
Breo ElliptaFluticasone/Vilanterol14$8,503
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,015
Albuterol Sulfate HfaAlbuterol Sulfate228$7,262
Cinacalcet Hcl11$6,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$94$176,219123 claims
Novo NordiskOzempic, Rybelsus$74$114,45072 claims
AstraZenecaFarxiga, Breztri Aerosphere$146$62,93453 claims
GSKTrelegy Ellipta, Breo Ellipta$597$57,81988 claims
Boehringer IngelheimJardiance$107$54,67741 claims
PfizerEliquis$209$54,06654 claims
MerckJanuvia, Janumet$69$33,93129 claims
AbbVieLinzess$288$13,25923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →